title: Elevated serum concentrations of soluble CD14 in HIV- and HIV+ patients with tuberculosis in Africa: prolonged elevation during anti-tuberculosis treatment.
abstract: Data are limited regarding serum concentrations of soluble CD14 (sCD14), a marker of macrophage activation, in patients with active tuberculosis (TB) and during drug treatment. In this study, concentrations of sCD14 were measured in serum samples obtained from 105 African subjects who were categorized into one of four groups: persons with pulmonary TB alone (TB+HIV-, n = 30), pulmonary TB and HIV co-infection (TB+HIV+, n = 20), or HIV infection alone (TB-HIV+, n = 25), and healthy controls (TB-HIV-, n = 30). Mean total sCD14 was significantly increased in serum of patients with newly diagnosed pulmonary TB (mean = 6.6 g/ml, s.d. = 1.6 g/ml) compared with healthy controls (mean = 3.1 g/ml, s.d. = 0.6 g/ml; P < 0.0001), and this elevation comprised proportionate increases in the alpha (2.1-fold greater, P < 0.0001) and beta (2.0-fold greater, P < 0. 0001) forms of sCD14. Total sCD14 was also increased in serum of HIV-infected patients (mean = 4.1 g/ml, s.d. = 1.9 g/ml; P < 0.01), but the highest concentrations were observed in patients with pulmonary TB and HIV co-infection (mean = 8.7 g/ml, s.d. = 3.1 g/ml; P < 0.0001). Analysis of serum samples prospectively collected from TB+HIV-patients during the first 3 months of successful anti-TB treatment demonstrated steep reductions in mean concentrations of the acute-phase protein, C-reactive protein, and the soluble lymphocyte activation marker, sCD25. In contrast, levels of sCD14 increased during the first month of treatment and slowly declined thereafter. These data indicate that the serum concentration of sCD14 is not a sensitive index of response to anti-TB treatment and suggest that cellular activation resolves more slowly in the macrophage pool compared with the lymphocyte pool during anti-TB treatment.
authors.affiliation: Division of Communicable Diseases, St George's Hospital Medical School, London, UK. dil3@cdc.gov
authors.forename: S D
authors.initials: SD
authors.lastname: Lawn
authors.forename: M O
authors.initials: MO
authors.lastname: Labeta
authors.forename: M
authors.initials: M
authors.lastname: Arias
authors.forename: J W
authors.initials: JW
authors.lastname: Acheampong
authors.forename: G E
authors.initials: GE
authors.lastname: Griffin
mesh_terms: D000328:Adult; D005260:Female; D018023:HIV Seronegativity; D006679:HIV Seropositivity / Q000097:blood* / Q000150:complications; D006801:Humans; D018950:Lipopolysaccharide Receptors / Q000097:blood*; D008262:Macrophage Activation; D008297:Male; D015375:Receptors, Interleukin-2 / Q000097:blood; D014376:Tuberculosis / Q000097:blood* / Q000150:complications
chemical_list: D018950:Lipopolysaccharide Receptors; D015375:Receptors, Interleukin-2